Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

Alnylam Pharmaceuticals specializes in RNA interference therapeutics, with Amvuttra being one of its key products targeting transthyretin-mediated amyloidosis, a rare and often fatal disease that can ...

Needham updated its Amvuttra revenue model and raised its out-year ATTR revenue estimates as a result of the meeting. The company’s overall revenue growth stands at 17.21%, with InvestingPro data ...

The research firm expressed increased optimism about Alnylam’s business prospects, particularly regarding the launch of Amvuttra for ATTR-CM, a form of cardiac amyloidosis. Needham updated its ...

Alnylam Pharmaceuticals specializes in RNA interference therapeutics, with Amvuttra being one of its key products targeting transthyretin-mediated amyloidosis, a rare and often fatal disease that ...